Tradicar, Practical Training Program In Diabetes For Today S Cardiologist

Abstract Introduction Diabetes Mellitus (DM) is an importan Cardiovascular Risk-factor and glucose-lowering drugs have shown to improve cardiovascular prognosis. We believe that specific training programs in DM are necessary, and so we have developed a web platform (Tradicar.es) to guide and provide educational tools. Objectives To evaluate characteristics of DM patients and the impact on active glycemic control strategies after the continuous training system. Methods We have created a web platform that allows direct consult with experts in diabetes and cardiology, immediately obtaining a recommendation. In addition, users have to propose a treatment, to evaluate their training progression. Prospectively, all DM patients admitted (Apr/18-Feb/19) were included. Personal history and preadmission, proposed and recommended treatment are recorded. For the comparison between proposed and recommended treatment we used a Cohen kappa, and for the comparison between previous and prescribed treatment, a chi-square test was performed. Results 117 patients were analyzed, 72 (64.9%) male, with a mean of 70.51 (±16.2) y.o. For other clinical variables see table. An active strategy was taken in 105 patients (89.7%), which resulted in an increased prescription of antidiabetic treatment. Specifically, SGLT2i prescription was significantly increased from 12 (10.9%) to 40 (34.2%) patients, p<0.01. The coincidence index increases from 0.76 (±0.21) in the first 4 months, to 0.9 (±0.2) in the last 4 months, p=0.03. Conclusions The cardiovascular prognostic impact of new glucose-lowering treatments forces us to to update and expand our DM training. Electronic tools allow immediate contact and are essential to improve the medical care we offer. Figure 1. A: Included patients (bars) and Cohen kappa (dots). B: Comparison of glucose-lowering drugs at hospitalization and discharge. Funding Acknowledgement Type of funding source: None